Business Wire

MAXON

10.4.2024 15:32:31 CEST | Business Wire | Press release

Share
Maxon One Spring 2024 Release Packs Particle Power, Toon Shading, and More

Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists, and creators of all types, today announced a game-changing update to Maxon One.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409558753/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Maxon One Spring 2024 release showcases groundbreaking updates to Cinema 4D, Redshift, Red Giant and more to enable users to bring stories to life with unparalleled creative freedom. Artist credit: Something's Awry

Motion designers, broadcasters, VFX artists, and more rely on Maxon One to promote products, frame shows, and realize clients’ visions. And, just in time for NAB, this spring release is packed with new creativity-boosting upgrades and tools, including Cinema 4D Particles, NPR rendering in Redshift, and Red Giant Geo.

Feature Highlights Include:

Cinema 4D 
Cinema 4D 2024.4 empowers 3D VFX artists and motion designers to create complex scenes with ease.

  • Design particle simulations intuitively with new Cinema 4D Particles! Integration with C4D’s Unified Simulation systems allows artists to control emission patterns, modify behaviors precisely, and orchestrate interactions with Maxon’s collection of simulation types, including Pyro, Cloth, soft bodies, and rigid bodies. Render particles scenes with Redshift, or cache and export them via Alembic. New Cinema 4D Particles presets are available in the Asset Browser, giving artists creative options for starting any project.

Redshift 
Redshift 3.6.0 features non-photorealistic rendering (NPR), more flexible Standard Volumes, support for AMD graphics, alpha mask support for Redshift area lights and more.

  • Render NPR line and toon looks in Redshift with new non-photoreal-render options, including a Contour node, a Toon Material node for cel shading, and a Tonemap Pattern shader for half-tone shading and other screen-space, grid-based shading styles.

Red Giant 
Red Giant 2024.2 features Red Giant Geo, a new tool that lets users texture, light, and clone 3D objects in After Effects. Rendering performance in Trapcode Particular has been improved significantly and there are new custom blur maps for Bokeh, as well as improvements to Looks’ UI.

Capsules 
Maxon One subscribers enjoy access to the expansive Maxon Capsules library, which includes a wide variety of assets to help kickstart any project. In addition to the library of Adobe Substance 3D materials Maxon released in partnership with Adobe recently, this release includes many great new additions such as Ivy Generator, Partition Modifier and Wood Floors Vol. 01.

Cineware 
Updates to Cineware for Unreal make it easier than ever to transfer materials between Cinema 4D to Unreal. Use Direct Link, and there’s no need to save files to disk when transferring. Note: Only works with Unreal Engine 5.0 and beyond and requires Cinema 4D 2023.0 or later versions.

More details at maxon.net. Assets are available to download here.

About Maxon 
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409558753/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye